Clinical Trial Update: A Controlled-Study of Fenofibrate 145 mg and Ezetimibe 10 mg in Type IIb Dyslipidemic Patients With Features of the Metabolic Syndrome [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update on a combination of fenofibrate and ezetimibe in Type IIb dyslipidemic patients with metabolic syndrome features; the study stat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia
• Hyperlipidemia
• Metabolic Syndrome

Drugs mentioned

• EZETIMIBE (EZETIMIBE)
• FENOFIBRATE (Fenofibrate)

Snippet

Sponsor: Solvay Pharmaceuticals | Conditions: Hyperlipidemia Combined | Phase 3 | Status: COMPLETED